See All Slides - tctmd.com

Slides

Presentation TCT 2013

Real-Time Device Surveillance

Presenter: Mladen Vidovich

October 30, 2013

Presentation TCT 2013

TCT-126. First-in-human experience with a novel high-flow percutaneous heart pump

Presenter: David Kandzari

October 30, 2013

Presentation TCT 2013

Should Innovative New Device Platforms (Like Bioresorbable Scaffolds) Be Studied Using Global All-Comer "Big Data" Clinical Trials Rather Than Smaller Indication-Focused RCTs?

Presenter: Mitchell Krucoff

October 30, 2013

Presentation TCT 2013

When is a Second Stent Required (Planned and Provisional)

Presenter: Goran Stankovic

October 30, 2013

Presentation TCT 2013

Enlightened Perspectives from NICE

Presenter: Amanda Adler

October 30, 2013

Presentation TCT 2013

Contracts 101: Practice Types and Payment Models

Presenter: Thomas Tu

October 30, 2013

Presentation TCT 2013

The Glucometabolic Milieu: Implications on Platelet Function in the PCI Patient

Presenter: Frederick Feit

October 30, 2013

Presentation TCT 2013

New Stents

Presenter: Sotirios Tsimikas

October 30, 2013

Presentation TCT 2013

Case #4: Complex CTO: The European Dual Approach

Presenter: Jose Rumoroso

October 30, 2013

Presentation TCT 2013

Motion: The Envelope for TAVR Should be Expanded to All Candidates for Conventional AVR - For: The Data are Clear (And Common Sense Rules): TAVR is a Lower Risk Option than...

Presenter: Daniel Blackman

October 30, 2013

Advertisement

Slides

Real-Time Device Surveillance

TCT-126. First-in-human experience with a novel high-flow percutaneous heart pump

Should Innovative New Device Platforms (Like Bioresorbable Scaffolds) Be Studied Using Global All-Comer "Big Data" Clinical Trials Rather Than Smaller Indication-Focused RCTs?

When is a Second Stent Required (Planned and Provisional)

Enlightened Perspectives from NICE

Contracts 101: Practice Types and Payment Models

The Glucometabolic Milieu: Implications on Platelet Function in the PCI Patient

New Stents

Case #4: Complex CTO: The European Dual Approach

Motion: The Envelope for TAVR Should be Expanded to All Candidates for Conventional AVR - For: The Data are Clear (And Common Sense Rules): TAVR is a Lower Risk Option than...

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content